CA-DISTRIBUTED-BIO
14.1.2020 12:02:16 CET | Business Wire | Press release
Distributed Bio , a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce a multi target research collaboration with John DiPersio, MD, PhD, Chief of the Division of Oncology at Washington University School of Medicine and Deputy Director of the Alvin J. Siteman Cancer Center in St. Louis. Distributed Bio will use its proprietary SuperHuman antibody discovery and engineering platform to discover and optimize therapeutics in collaboration with Dr. DiPersio.
“We are delighted to collaborate with Dr. DiPersio on antibody discovery,” says Jacob Glanville, Co-Founder and Chief Executive Officer of Distributed Bio. “The SuperHuman Platform represents the culmination of a decade of our research in computational library design. From analyzing thousands of human immune systems with our machine learning AbGenesis platform, we have harvested from nature the rules of making exceptional therapeutic repertoires. The result is a library of 76 billion antibodies that contains over 5,000 hits against any antigen, thermostable, non-immunogenic, pre-screened by human blood and therapeutically developed in advance to avoid engineering delays downstream. This is an order of magnitude more molecules than can be generated by other technologies, and enables our partners to search for ultra-specific, species-cross reactive therapeutic antibodies at unprecedented speeds. The libraries overcome many of the limitations of other monoclonal generation technologies that have resulted in a unique engineering opportunity: a library that can generate unique and developable hits against every antigen tested, enabling routine success against targets that used to be nearly insurmountable – GPCRs, Ion Channels, pMHC complexes, broadly-neutralizing antibodies against HIV, therapeutic anti-idiotypic antibodies, bi-epitopic antibodies, and mouse/NHP/human cross-reactive antibodies.”
Under the terms of the collaboration, Distributed Bio will use its SuperHuman antibody library to discover novel therapeutic antibodies to targets selected by Dr. DiPersio and will also use its Tumbler technology to optimize clones that he already has identified. The lead clones will then be further developed by Dr. DiPersio.
About Distributed Bio
Distributed Bio is a computational immunoengineering biotechnology group, self-funded by the success of the stack of antibody discovery, optimization and analysis technologies to partners across the pharmaceutical industry. Our mission is to disrupt biologic engineering with big data, machine learning, and computational immunology-driven design.
From a team that includes inventors of antibody repertoire sequencing technologies, their AbGenesis antibody and TCR repertoire analysis and engineering platform enables partners to analyze antibody repertoires by high-throughput sequence, Sanger sequence, and functional assay without requiring large data center investments or local bioinformatics specialists. By using AbGenesis to analyze thousands of antibody repertoires and antibody libraries, they developed the computationally optimized SuperHuman 2.0 antibody library, the SLiC single light chain library, the Tungsten humanized VHH library, CAR-T discovery library, and the Cosmic antibody library.
In 2018, Distributed Bio entered into an exclusive partnership with Charles River, a leading provider of essential products and services for pharmaceutical and biotechnology companies, government agencies and leading academic institutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005196/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply and IEO Launch Collaboration to Co-Develop and Train Domain-Specific Large Language Models for Oncology4.6.2026 10:10:00 CEST | Press release
Reply [EXM, STAR: REY] and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. The initiative brings together Reply’s expertise in building frontier generative models grounded in enterprise knowledge with the IEO’s clinical expertise and data assets to develop models tailored to highly complex oncology settings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604488955/en/ Reply and the European Institute of Oncology (IEO) have launched a collaboration focused on the co-development and training of domain-specific Large Language Models for oncology. As a first step, the IEO’s clinical teams and Information Systems department are working with a multidisciplinary Reply team with deep expertise in healthcare and LLM specialisation to define and prioritise the use cases that will guide development, while also map
UK AI Minister Kanishka Narayan Joins The AI Summit London as 10th Anniversary Agenda Expands Across Enterprise AI, Innovation and Policy4.6.2026 10:00:00 CEST | Press release
London Tech Week's flagship AI event will feature 300 speakers, live AI demonstrations, startup pitch competitions, executive training and the National AI Awards The AI Summit London today revealed the full agenda for its highly anticipated 10th anniversary edition, delivering its most expansive and future-focused programme to date. Taking place 10–11 June at Tobacco Dock as the headline AI event of London Tech Week 2026, the Summit expects more than 5,000 attendees, 300 speakers, 100+ sponsors and exhibitors, and a special executive presentation from Kanishka Narayan, Minister for AI and Online Safety, Department for Science, Innovation and Technology, across two days dedicated to the commercial realities and transformative potential of artificial intelligence. The 10th anniversary has been designed to move the conversation beyond experimentation and into enterprise-wide execution. New in 2026, the programme introduces The AI Impact Arena, delivering focused briefings and live demos,
Corona Launches 2026 Beach 100 Guide, Invites The World To Explore The Outdoors This Summer4.6.2026 10:00:00 CEST | Press release
Ahead of World Oceans Day, the global beach authority returns with a list of new locations, over 300,000 Tripadvisor experiences, and dedicated beach grants as part of its “This is Living” platform Corona, the world’s most valuable beer brand1, today announced the return of its annual global beach guide, the 2026 Corona Beach 100, ahead of World Oceans Day on June 8. The highly anticipated second edition spotlights 100 breathtaking and varied ocean-front destinations around the world while celebrating the natural ecosystems and local communities that help bring them to life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604412899/en/ 2026 Corona Beach 100 - Legzira Beach, Morocco Connected to Corona’s “This Is Living” platform, which invites consumers to step outside and live life to the fullest this summer, the 2026 guide features 27 new beaches, hundreds of localized Tripadvisor travel experiences inspired by the world
Lantern Expands Its Platform for Solving the Data Trust Problem with Strategic Acquisition and Key Executive Hires4.6.2026 10:00:00 CEST | Press release
Lantern Acquires Freyda to Create the First End-to-End Data Assurance Platform for Private Markets Lantern Limited (“Lantern”), the data assurance platform for private markets, announced today a strategic acquisition, expanded platform capabilities, and key leadership additions to address one of private markets biggest operational challenges: transforming fragmented, disconnected data across multiple sources into trusted, actionable intelligence. Private markets run on data, yet much of that data remains siloed, trapped in PDFs, and processed through highly manual workflows across both fund managers and investors. While GPs have increasingly modernized how they manage and report fund information internally, LPs still spend billions of dollars each year manually extracting, normalizing, and reconciling data from capital notices, quarterly statements, and other fund documents. With the acquisition of Freyda Limited (“Freyda”), one of the leading AI document intelligence platforms for ins
KAYTUS Launches MotusAI Enterprise Token Management Platform4.6.2026 09:02:00 CEST | Press release
KAYTUS, a leading provider of AI infrastructure and liquid cooling solutions, today announced the launch of enterprise-grade token management capabilities within MotusAI, enabling organizations to rapidly build, deploy, and operate secure on-premises AI token platform. This pioneering infrastructure enhancement transforms traditional GPU hardware into a unified, governable, and highly efficient internal token service ecosystem. By enabling rapid private deployment, MotusAI provides enterprises with a cost-competitive foundation for accelerating the scale-up of enterprise-grade AI agents while ensuring strong data privacy. Why Enterprises Must Build a Private Token Management Platform Now? As enterprise AI evolves from isolated model-based tools to interconnected AI agent systems that enable deep workflow automation, tokens are emerging as the fundamental “computing currency” of the modern organization. While standard LLM queries typically involve predictable, one-off inference requests
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom